Aaron Jasso
Family · Roswell, NMNPI 1811334246
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 69.0% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $2,528, more than ten times the $200 reported in 2021. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $45.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Harmony Biosciences LLC$161
- Mayne Pharma Commercial LLC$148
- Axsome Therapeutics, Inc.$140
- Novo Nordisk$125
- Alkermes, Inc.$110
- plus $625 from 14 others
What the payments were for
- Speaking & faculty fees$2,50059%
- Travel & lodging$1042%
- Food & beverage$1,61238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $2,907 |
| Harmony Biosciences LLC | 6 | $161 |
| Mayne Pharma Commercial LLC | 1 | $148 |
| Axsome Therapeutics, Inc. | 6 | $140 |
| Novo Nordisk | 4 | $125 |
| Alkermes, Inc. | 6 | $110 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Lundbeck LLC | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Braeburn Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Genentech USA, Inc. | 2 | $16 |
| Organon | 1 | $15 |
| Laborie Medical Technologies Corp. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,604
How this compares
$4,216 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 39 | $60,747 |
| Risperidone | 42 | $1,134 |
| Carbamazepine | 14 | $876 |
| Olanzapine | 50 | $864 |
| Sertraline Hcl | 89 | $702 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 55 | $643 |
| Aripiprazole | 16 | $522 |
| Divalproex Sodium | 13 | $466 |
| Bupropion XlBupropion Hcl | 28 | $387 |
| Topiramate | 25 | $384 |
| Hydroxyzine Pamoate | 20 | $376 |
| Doxepin Hcl | 12 | $368 |
| Trazodone Hcl | 35 | $322 |
| Mirtazapine | 29 | $313 |
| Clonazepam | 25 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,907 | $60,74739 claims |
| Lilly USA, LLCOlanzapine | $48 | $86450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Roswell
- Carol HollandRoswell$81K
- Jessie SurlaRoswell$6K
- Kristy BellRoswell$6K
- David SeiterFarmington$194K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.